Sonnet biotherapeutics announces issuance of u.s. patent covering a variant il-18 incorporated into two novel immunotherapeutic drug candidates

Both novel bifunctional (son-1411) and monofunctional (son-1400) fusion proteins exhibit wild-type binding to the il-18 receptor (il-18rc), coupled with undetectable binding to the inhibitory il-18 binding protein (il-18bp)

SONN Ratings Summary

SONN Quant Ranking